{"id":390415,"date":"2019-05-24T00:00:00","date_gmt":"2019-05-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2019-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2019\/"},"modified":"2026-05-02T11:36:25","modified_gmt":"2026-05-02T11:36:25","slug":"algocg0032-2019-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2019-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2019\/","title":{"rendered":"Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2019"},"content":{"rendered":"<p>With over a dozen immunomodulatory disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) available to treat multiple sclerosis (<abbr title=\"multiple sclerosis\">MS<\/abbr>) and many more in the pipeline, the treatment journey for U.S.\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0patients continues to evolve. To date, the\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0market has accommodated a role for all current therapies due to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each\u00a0<abbr title=\"disease-modifying therapy\">DMT<\/abbr>. That said, with each new launch, players in the\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0space\u2014new and seasoned alike\u2014must assess where their products fit into an increasingly crowded market. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain a source of debate, further stoked by the launch of Roche \/ Genentech\u2019s Ocrevus. This national patient-level claims data analysis explores the current\u00a0<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s\u2019 positioning, examines line of therapy progression, and assesses persistence and compliance by brand.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key brands garner by line of therapy in newly diagnosed\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0patients?<\/li>\n<li>How have new entrants been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>\u00a0What percentage of\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong>\u00a0United States<\/p>\n<p><strong>Real-world data:\u00a0<\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key companies:\u00a0<\/strong>Bayer, Novartis, EMD Serono \/ Pfizer, Biogen, Teva, Sandoz, Sanofi Genzyme, Genentech \/ Roche<\/p>\n<p><strong>Key drugs covered:\u00a0<\/strong>Aubagio, Copaxone \/ glatiramer acetate, Gilenya, interferons (all), Lemtrada, Ocrevus, Tecfidera, Tysabri<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand\/therapy usage across a longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowchart.<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390415","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390415\/revisions"}],"predecessor-version":[{"id":393540,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390415\/revisions\/393540"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}